Related references
Note: Only part of the references are listed.Mapping the human DC lineage through the integration of high-dimensional techniques
Peter See et al.
SCIENCE (2017)
Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan
Kouji Kobiyama et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Adaptive immunity in HBV infection
Antonio Bertoletti et al.
JOURNAL OF HEPATOLOGY (2016)
Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells
Yuji Kitahata et al.
ONCOTARGET (2016)
Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection
Takuya Yamamoto et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The Chemokine System in Innate Immunity
Caroline L. Sokol et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)
Interferon-Stimulated Genes: A Complex Web of Host Defenses
William M. Schneider et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist
Kouji Kobiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models
Takahiro Tougan et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
C. Manegold et al.
ANNALS OF ONCOLOGY (2012)
Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates
Marcin Kwissa et al.
BLOOD (2012)
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells
Petra Baumgaertner et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Safety and Immunogenicity of Vaccination With MART-1 (26-35, 27L), gp100 (209-217, 210M), and Tyrosinase (368-376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Virus Inhibition Activity of Effector Memory CD8+ T Cells Determines Simian Immunodeficiency Virus Load in Vaccinated Monkeys after Vaccine Breakthrough Infection
Takuya Yamamoto et al.
JOURNAL OF VIROLOGY (2012)
IL-12 family cytokines: immunological playmakers
Dario A. A. Vignali et al.
NATURE IMMUNOLOGY (2012)
Phase 1 Study in Malaria Naive Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria
Ruth D. Ellis et al.
PLOS ONE (2012)
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
Benjamin P. Sablan et al.
VACCINE (2012)
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age
Scott A. Halperin et al.
VACCINE (2012)
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
Julia Karbach et al.
CLINICAL CANCER RESEARCH (2011)
Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
Christopher J. A. Duncan et al.
PLOS ONE (2011)
Monocyte trafficking in acute and chronic inflammation
Molly A. Ingersoll et al.
TRENDS IN IMMUNOLOGY (2011)
Vaccine Adjuvants: Putting Innate Immunity to Work
Robert L. Coffman et al.
IMMUNITY (2010)
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai et al.
NATURE IMMUNOLOGY (2010)
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Joerg Vollmer et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
The TLR9 Ligand CpG Promotes the Acquisition of Plasmodium falciparum-Specific Memory B Cells in Malaria-Naive Individuals
Peter D. Crompton et al.
JOURNAL OF IMMUNOLOGY (2009)
A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals
Ruth D. Ellis et al.
VACCINE (2009)
Dendritic cells in vivo: A key target for a new vaccine science
Ralph M. Steinman
IMMUNITY (2008)
Cellular and humoral immune response to a third generation hepatitis B vaccine
A. Schumann et al.
JOURNAL OF VIRAL HEPATITIS (2007)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
DE Speiser et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
CL Cooper et al.
VACCINE (2004)
Modulating vaccine responses with dendritic cells and Toll-like receptors
B Pulendran
IMMUNOLOGICAL REVIEWS (2004)
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist
AM Krieg et al.
JOURNAL OF IMMUNOTHERAPY (2004)
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults:: A double-blind phase I/II study
CL Cooper et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
Cyclooxygenase-selective inhibition of prostanoid formation:: transducing biochemical selectivity into clinical read-outs
C Patrono et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
